Trial Profile
ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Oct 2014 New trial record